Cargando…

An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report

BACKGROUND: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliato, Debora de Melo, Linck, Rudinei Diogo Marques, Bezerra, Regis Otaviano Franca, Souto, Mirela, Lopes, Gabriel Lima, Baiocchi, Glauco, Mano, Max Senna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790046/
https://www.ncbi.nlm.nih.gov/pubmed/26971567
http://dx.doi.org/10.1186/s13256-016-0837-3
Descripción
Sumario:BACKGROUND: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case report represents the first-ever reported objective response to a metronomic chemotherapy regimen and adds to the current literature. CASE PRESENTATION: We describe a case of a Caucasian woman diagnosed with metastatic carcinosarcoma that had already been treated with multiple lines of conventional chemotherapy, with progressive disease. This patient had a surprising clinical and imaging response when treated with oral metronomic cyclophosphamide. CONCLUSIONS: We reviewed the mechanism of action implicated in metronomic chemotherapy, and correlated it with the biology of disease in carcinosarcoma. This information may add to the current literature, providing important insights to future clinical trials in this patient population.